BPC 157 Reverses Schizophrenia-Like Catalepsy in Rat Models

Schizophrenia is a complex neurological disorder characterized by various symptoms, including positive-like symptoms such as catalepsy (a trance-like state with rigidity). The nitric oxide (NO) system plays a critical role in brain function, and its dysregulation is implicated in neuropsychiatric conditions. This study investigated whether the stable gastric pentadecapeptide BPC 157 could counteract catalepsy induced by L-NAME, a nitric oxide synthase inhibitor, in acute and chronic rat models resembling schizophrenia.

The study consistently demonstrated that BPC 157 significantly reduced L-NAME-induced catalepsy across both acute and chronic models. In acute settings, BPC 157 at doses like 10 µg/kg or 10 mg/kg effectively attenuated catalepsy scores, showing a dose-dependent effect. This counteracting effect was robust, with catalepsy scores reduced by up to 70% compared to L-NAME-treated controls (p<0.01). The efficacy of BPC 157 was comparable to, and in some instances superior to, that of L-arginine, which also mitigated L-NAME-induced effects. Furthermore, BPC 157 maintained its therapeutic benefits in chronic L-NAME models, suggesting sustained modulation of the NO system. > The most important finding was that BPC 157 consistently and significantly counteracted L-NAME-induced catalepsy in rats, demonstrating a potent modulatory effect on the nitric oxide system and reducing catalepsy scores by up to 70% (p<0.01) compared to control groups. These results indicate that BPC 157 can effectively normalize motor disturbances associated with NO system imbalance.